Rick Modi, Affinia Therapeutics CEO
December 5, 2022 08:26 AM ESTUpdated December 6, 07:06 AM
Financing
Startups
Cell/Gene Tx

Ver­tex-part­nered gene ther­a­py biotech Affinia scraps IPO plans

Kyle LaHucik

Senior Reporter

Affinia Ther­a­peu­tics has ditched its plans to go pub­lic in a rel­a­tive­ly closed-door mar­ket that has not fa­vored Nas­daq de­buts for the drug de­vel­op­ment in­dus­try …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times